Many recent clinical and research results show deprivation of glucose in brain to cause early stage Alzheimer’s disease, such as the study published on 1-31-2017 by the researchers in the medical school of Temple University. However, some study results may cause confusions without expertise analysis. For example, Yang and colleagues published an article “Evidence for brain glucose dysregulation in Alzheimer’s disease (Alzheimer’s & Dementia 14, 2018). This study correlated higher glucose level and diminished activity of glycolysis enzyme found in deceased AD patients. It ignored the clinical symptoms of nightmares, night sweats, and hallucinations that exist in most early stage AD patients. Those symptoms are typical of nocturnal hypoglycemia trigged rebound through hormonal rescue mechanism. It also ignored their own data that showed fasting glucose level correlation and failed to relate typical causes of Somogyi effect. Their conclusion should have emphasized the importance of early intervention of AD patients with a timed supply of glucose at bedtime, instead of vague suggestion of higher glucose level causing the disease.
Thus, clinicians and caregivers should concentrate on their own knowledge of symptoms of AD patients, otherwise it can be misled by some studies.